Clinical applications of DNA methylation biomarkers in colorectal cancer

Epigenomics

Volumn 5, Issue 2, 2013, Pages 105-108

  Lange, Christopher Pe ^a   Laird, Peter W ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

biomarkers; colorectal cancer; DNA methylation; epigenetics; epigenomics

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; COLORECTAL ADENOMA; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; EARLY INTERVENTION; FAMILY HISTORY; GENE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; MORBIDITY; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; HUMANS; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84876139704     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.4     Document Type: Review

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Draht MX, Riedl RR, Niessen H et al. Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics 4(2), 179-194 (2012).
3. Hitchins MP, Rapkins RW, Kwok CT et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5́UTR. Cancer Cell 20(2), 200-213 (2011).
4. Mrkonjic M, Roslin NM, Greenwood CM et al. Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSIH colorectal cancer. PLoS ONE 5(10), e13314 (2010).
5. Cui H, Cruz-Correa M, Giardiello FM et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299, 1753-1755 (2003). (Pubitemid 36337205)
6. Febbo PG, Ladanyi M, Aldape KD et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J. Natl Compr. Canc. Netw. 9(Suppl. 5), S1-32; quiz S33 (2011).
7. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11(6), 426-437 (2011).
8. Herbst A, Wallner M, Rahmig K et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur. J. Gastroenterol. Hepatol. 21(5), 565-569 (2009).
9. Lofton-Day C, Model F, Devos T et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54(2), 414-423 (2008). (Pubitemid 351302625)
10. Ahlquist DA, Zou H, Domanico M et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142(2), 248-256 (2012).
11. Warren JD, Xiong W, Bunker AM et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9, 133 (2011).
12. Bosch LJ, Oort FA, Neerincx M et al. DNA Methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev. Res. (Phila) 5(3), 464-472 (2012).
13. Ahlquist DA, Taylor WR, Mahoney DW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 10(3), 272.e1-277.e1 (2012).
14. Lofton-Day C, Model F, Devos T et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54(2), 414-423 (2008). (Pubitemid 351302625)
15. Tang D, Liu J, Wang DR, Yu HF, Li YK, Zhang JQ. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin. Invest. Med. 34(2), E88-E95 (2011).
16. Lange CP, Campan M, Hinoue T et al. Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS ONE 7(11), e50266 (2012).
17. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681-8686 (1999). (Pubitemid 29354851)
18. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787-793 (2006). (Pubitemid 43980599)
19. Issa JP. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4, 988-993 (2004).
20. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003). (Pubitemid 36859476)
21. Van Rijnsoever M, Elsaleh H, Joseph D, Mccaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9(8), 2898-2903 (2003). (Pubitemid 36993247)
22. Jover R, Nguyen TP, Perez-Carbonell L et al. 5Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140(4), 1174-1181 (2011).
23. Ebert MP, Tanzer M, Balluff B et al. TFAP2EDKK4 and chemoresistance in colorectal cancer. N. Engl. J. Med. 366(1), 44-53 (2012).